All In Biotech

Free tool

FAERS Monitor: Azasite

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 050810 or its brand name (Azasite, Azithromycin). Reports on generic versions are filed under their own applications.

Reports

1,475

Serious

351

24% of reports

Hospitalization

170

Death reported

25

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • no adverse event421
  • drug dose omission329
  • product quality issue276
  • inappropriate schedule of drug administration211
  • eye irritation195
  • product packaging quantity issue146
  • off label use143
  • drug ineffective132
  • eye pain105
  • eye pruritus105
  • dyspnoea102
  • lacrimation increased91
  • ocular hyperaemia91
  • asthma82
  • cough80

Reports by year received

View as table
YearReports
20073
200816
200912
201014
201115
2012201
2013481
201443
201534
201664
201736
201839
201972
2020118
202173
202265
202367
202439
202538
202645

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,684 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product packaging quantity issueSignal146186.6159.826,442
eye irritationSignal19548.542.59,013
eye pruritusSignal10544.737.24,435
lacrimation increasedSignal9143.135.33,692
inappropriate schedule of drug administrationSignal21142.437.48,495
no adverse eventSignal42133.230.613,202
product quality issueSignal27629.026.17,476
drug dose omissionSignal32928.425.88,732
ocular hyperaemiaSignal9127.422.42,289
eye painSignal10526.622.12,562
asthmaSignal8210.48.4687
coughSignal804.13.3185
dyspnoeaSignal1022.62.199
off label useSignal1432.32.0112
drug ineffective1321.41.218

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.